SCHEDULE 13D: Value Base LP Challenges Perion Network's 'Poison Pill' Defense, Demands Shareholder Vote

Value Base LP, a significant shareholder in Perion Network Ltd., has filed a Schedule 13D to formally oppose the company's recently adopted 'Poison Pill' mechanism, citing shareholder harm and governance concerns.

Summary

• Value Base Ltd. and its affiliates (Value Base Fund Management Ltd., Ido Nouberger, and Victor Shamrich), collectively the Reporting Persons, have disclosed a beneficial ownership of 2,632,789 Ordinary Shares of Perion Network Ltd., representing approximately 5.85% of the outstanding shares.
• Since January 6, 2025, Value Base Fund Limited Partnership (VBF LP) has invested approximately $22.5 million of its equity to acquire these shares.
• The primary purpose of this filing is to formally object to Perion Network Ltd.'s adoption of a 'Poison Pill' (Rights Plan) on April 3, 2025.
• The Poison Pill grants other shareholders the right to purchase 0.5 shares for $0.01 if any shareholder reaches a 13% or more holding without Board approval.
• Value Base asserts that the Poison Pill is detrimental to shareholders, potentially adopted in violation of law and the company's articles of association, and raises concerns about conflicts of interest within the Board of Directors.
• The Reporting Persons have demanded that Perion's Board either rescind the Poison Pill or submit it to a shareholder vote at a general meeting within seven business days from April 21, 2025.
• They are considering further actions, including calling for a general meeting and engaging in discussions with management, the Board, and other securityholders to encourage withdrawal or prevent implementation of the Poison Pill.

Sentiment

Score: 3

Explanation: The sentiment is negative towards Perion Network Ltd.'s management action (Poison Pill) but positive in terms of shareholder activism and advocacy for corporate governance. The filing itself is a challenge, indicating dissatisfaction with current management decisions.

Positives

• A significant shareholder group is actively advocating for what it perceives as the best interests of all shareholders by challenging a controversial corporate defense mechanism.
• The filing highlights a commitment to corporate governance and shareholder rights by demanding a shareholder vote on a material corporate action.

Negatives

• The adoption of the 'Poison Pill' by Perion Network Ltd.'s Board of Directors is viewed by Value Base as harmful to shareholders and potentially in violation of legal and corporate governance standards.
• Concerns are raised regarding potential conflicts of interest among the Board members in approving the Poison Pill.
• The company's report on the Poison Pill is alleged to be deficient and misleading.
• The activation of the Poison Pill could expose the company to delisting from the Tel Aviv Stock Exchange.
• The company and its office holders are exposed to potential litigation due to the adoption of the Poison Pill.

Risks

• Potential delisting from the Tel Aviv Stock Exchange if the Poison Pill is activated.
• Exposure of the company and its office holders to litigation due to the adoption of the Poison Pill.
• The Poison Pill may cause greater damages, losses, and losses of profits to shareholders if not rescinded or approved by shareholders.
• The Board's resolution to adopt the Poison Pill could materially harm shareholders.

Future Outlook

The Reporting Persons intend to continuously review their investment in Perion Network Ltd. and may acquire additional securities, or retain or sell existing holdings, based on ongoing evaluation of the Issuer's business, financial condition, market conditions, and alternative opportunities. They plan to take further actions to compel the Company to withdraw the Poison Pill or subject it to a shareholder vote, including potentially calling for a general meeting of shareholders and engaging in discussions with various stakeholders to encourage changes in corporate governance or structure.

Industry Context

This filing highlights a growing trend of shareholder activism, particularly concerning corporate governance issues like 'Poison Pills' which are often viewed by activist investors as anti-takeover defenses that entrench management and dilute shareholder value. The dual listing on Nasdaq and the Tel Aviv Stock Exchange adds complexity, as different regulatory environments and investor expectations may apply. The challenge to the Poison Pill aligns with broader investor demands for increased transparency and shareholder empowerment in corporate decision-making.

Comparison to Industry Standards

• The 'Poison Pill' mechanism, while a legal defense strategy, is often viewed negatively by corporate governance advocates and institutional investors as it can deter legitimate takeover bids and reduce shareholder returns. Many institutional investors and proxy advisory firms, such as ISS and Glass Lewis, generally recommend voting against or withholding votes from directors who adopt or maintain poison pills without shareholder approval.
• The demand for a shareholder vote on such a significant corporate defense mechanism aligns with best practices in corporate governance, which emphasize shareholder democracy and the right of owners to approve material changes affecting their investment.
• The filer's argument that the Poison Pill was adopted in violation of law and the company's articles of association, and with conflicts of interest, suggests a deviation from expected legal and ethical standards for board conduct in publicly traded companies.
• The mention of Perion's 'classified board' as an existing protective provision indicates that the company already has governance structures that can make hostile takeovers more difficult, making the additional Poison Pill potentially excessive compared to common industry practices for shareholder protection.

Corporate Governance

Legal Proceedings

• The adoption of the Poison Pill is stated to expose the Company and its office holders to litigation.

Stakeholder Impact

• **Shareholders**: The Poison Pill is argued to cause damage, losses, and loss of profits. The demand for a shareholder vote aims to protect their rights and interests. The potential for delisting from the Tel Aviv Stock Exchange could negatively impact liquidity and investor confidence.
• **Board of Directors/Management**: Accused of acting in conflict of interest and against shareholder interests. They face demands to rescind the Poison Pill or submit it to a vote, and are exposed to potential litigation.
• **Regulatory Authorities (SEC, Tel Aviv Stock Exchange)**: The filing highlights potential violations of securities laws and listing rules, which could trigger regulatory scrutiny.

Next Steps

• Perion Network Ltd.'s Board of Directors is demanded to either rescind the Poison Pill or submit it to a shareholder vote within seven business days from April 21, 2025.
• The Reporting Persons are considering additional actions, including calling for a general meeting of shareholders.
• Discussions with Perion's management, Board of Directors, other securityholders, and relevant parties are anticipated.
• The Reporting Persons may acquire additional securities or sell existing holdings based on ongoing evaluations.
• They may seek to cause the Issuer to consider or explore material changes related to corporate governance (e.g., articles of association), business, or corporate structure.

Key Dates

Keywords

Perion Network Ltd., Value Base, Schedule 13D, Poison Pill, Rights Plan, Shareholder Activism, Corporate Governance, Beneficial Ownership, SEC Filing, Tel Aviv Stock Exchange, Nasdaq, Shareholder Rights